Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,180 across all filing types
Latest filing 2022-10-27 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Board Meeting — Financial results/Other business matters
Regulatory Filings Classification · 95% confidence The document is a short notice from the company Lupin Limited addressed to stock exchanges, informing about a forthcoming Board of Directors meeting scheduled for November 9, 2022. The purpose of the meeting includes considering and taking on record the unaudited financial results for the quarter and half year ended September 30, 2022. The document is brief (1576 characters) and serves as an announcement of an upcoming event rather than containing any financial data or results itself. It does not include actual financial statements or detailed analysis. According to the rules, such a notice is not the financial report itself but an announcement related to the report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-10-27 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product (Paliperidone Extended-Release Tablets) in the USA by Lupin Limited. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI Listing Regulations, which typically covers material events or information about the company. The document is short (3815 characters), contains no financial statements or detailed financial analysis, and is primarily an announcement of a business event rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Earnings Release, or Management Reports. It is not a voting result, board change, or legal proceeding. The best fit is a Regulatory Filing (RNS) as a general disclosure of material information to the market under listing obligations.
2022-10-20 English
Lupin Launches Paliperidone Extended-Release Tablets in the United States.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product (Paliperidone Extended-Release Tablets) in the USA by Lupin Limited. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI Listing Obligations and Disclosure Requirements, 2015. The content is a corporate announcement about a product launch, not a financial report, earnings release, or regulatory filing about financials or governance. The document length is 3817 characters, which is relatively short and consistent with a press release or announcement. There is no financial data, no discussion of financial results, no voting results, no management changes, no audit information, and no legal proceedings. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-10-20 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, announcing that Lupin Inc., USA, a wholly owned subsidiary, has signed a definitive agreement to acquire two inhalation brands from Sunovion Pharmaceuticals Inc. The document includes details about the acquisition such as the purchase price, nature of consideration, and background of the acquired brands. It also contains a press release elaborating on the acquisition and its strategic importance. There are no financial statements or detailed financial performance data included, nor is this a full annual or interim report. The document is an announcement of a capital transaction (acquisition) and financing activity related to the company's business. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the acquisition, not merely a brief notification or regulatory filing. Confidence is high given the clear content and context.
2022-10-20 English
Lupin Signs Agreement to Acquire Two Inhalation Brands from Sunovion.
Capital/Financing Update Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, announcing that Lupin Inc., a wholly owned subsidiary, has signed a definitive agreement to acquire two inhalation brands from Sunovion Pharmaceuticals. It includes details about the acquisition such as the purchase price, nature of consideration, and business rationale. The document also contains a press release providing further information about the acquisition and the company. There are no financial statements or detailed financial performance data presented, nor is this a full report or earnings release. The content is an announcement of a capital transaction (acquisition) and financing activity related to the company's business. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the transaction, not merely a brief notification or regulatory filing. Hence, it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA).
2022-10-20 English
General updates
Regulatory Filings Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding an update on the company's biotech manufacturing facility inspection by the U.S. FDA. It is a regulatory announcement informing the stock exchanges and public about the inspection outcome and the company's response. The document is short (1992 characters) and does not contain financial statements or detailed financial data. It is not an annual or interim report, earnings release, or any detailed financial or management report. It is a regulatory filing informing about a material event related to compliance and inspection. Therefore, it fits best under Regulatory Filings (RNS).
2022-10-19 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.